ORCHID CHEM, INDO RAMA AND MASTEK Q2 RESULTS

Orchid Chemicals and Pharmaceuticals recorded a net profit of Rs 27.22 crore in the second quarter of 2005-06, a rise in 587 per cent compared with the Rs 3.96 crore recorded in the corresponding quarter of the previous year. The company's new formulation launches in the US postively affected its performance. The launch of an injectible, Ceftriaxone, during the second quarter also had a significant impact. Orchid's turnover in the second quarter of 2005-06 increased by 46.12 per cent to Rs 239.32 crore (Rs 163.77 crore in Q2 of FY05).

Business Standard (http://www.business-standard.com/common/storypage.php?storyflag=y&leftnm=lmnu1&leftindx=1&lselect=3&chklogin=N&autono=202954)